Due to the similar structure of the curcuphenol analogues to a known HDAC inhibitor, TSA, which promotes the expression of MHC-I in the metastatic A9 lung cancer cells (Setiadi et al., 2005a; Setiadi et al., 2007a; Setiadi et al., 2008a), it was predicted that the analogues were acting through a similar mechanism involving by HDAC inhibition. The gene discussed is HDAC9; the disease is lung carcinoma.